Marketing Strategies in the Competition between Branded and Generic Antibiotics (A): Clamoxyl in 1996 - Normandie Université Access content directly
Other Publications Year : 2007

Marketing Strategies in the Competition between Branded and Generic Antibiotics (A): Clamoxyl in 1996

Abstract

In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beecham's (SB) blockbuster antibiotic. Pierre Chahwakilian, Marketing Director of SB in France must decide how to respond: (1) milk Clamoxyl and divert promotional investments towards Augmentin, a more specialized and still patent-protected antibiotic, (2) strengthen Clamoxyl¿s brand equity among doctors by increasing the effort of medical reps, by launching new forms, or with new advertising, (3) go against SB¿s corporate philosophy and reduce the price of Clamoxyl, or (4) change nothing and count on the resistance of French doctors towards generics. The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should be followed?
No file

Dates and versions

hal-02904502 , version 1 (22-07-2020)

Identifiers

  • HAL Id : hal-02904502 , version 1

Cite

Pierre Chandon, Sarah Spargo, Olivier Kovarski, Jacques Lendrevie, Marc Vanhuele. Marketing Strategies in the Competition between Branded and Generic Antibiotics (A): Clamoxyl in 1996: REF: 5057(A). 2007, 40 p. ⟨hal-02904502⟩
121 View
0 Download

Share

Gmail Facebook X LinkedIn More